The COVID-19 pandemic generated partnerships among organizations with the goal of changing the way in which assay development and tech transfer of these assays are conducted moving forward.
Luc Gagnon
Advertisement
Luc Gagnon, PhD, is vice-president of Vaccine Sciences at Nexelis.
Articles by Luc Gagnon
Partnerships formed during the COVID-19 pandemic have provided a platform for change in assay development and transfers that should continue in the future.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
FDA Approves Roche’s Enspryng as First At-Home Subcutaneous Treatment for Thyroid Eye Disease
2
Estuary Biotherapeutics Launches With $103 Million for ADPKD Gene Therapy
3
Roche, Hansoh Sign Second ADC Pact Covering Preclinical and Roche-Selected Targets
4
BioPharm Brief: Gene Therapy Progress, FDA Approval, and $103M Funding
5